Augmented epithelial endothelin-1 expression in refractory asthma

J Allergy Clin Immunol. 2007 Dec;120(6):1301-7. doi: 10.1016/j.jaci.2007.09.023. Epub 2007 Nov 9.

Abstract

Background: Airway remodeling in patients with severe steroid-refractory asthma might result from a reduced ability of steroid therapy to limit the transcription of remodeling factors by the bronchial epithelium.

Objective: We sought to compare the levels of transcripts encoding remodeling factors in bronchial epithelium of healthy volunteers and of asthmatic patients with either steroid-sensitive or steroid-refractory disease and to correlate these levels with hallmarks of airway remodeling.

Methods: By means of real-time quantitative PCR, we assessed the levels of 14 transcripts encoding remodeling factors, matrix metalloproteinases, and extracellular matrix proteins in laser-capture microdissected bronchial epithelium of healthy volunteers, patients with mild steroid-untreated asthma, and patients with steroid-sensitive and steroid-refractory asthma (n = 8-10 in each group). Histologic features of airway remodeling and endothelin-1 (EDN1) immunolocalization were determined by using frozen specimens.

Results: Patients with steroid-refractory asthma had greater levels of EDN1 transcripts (4.1-fold increase, P = .026) and protein (P = .0009) in their bronchial epithelium compared with patients with steroid-sensitive asthma. EDN1 mRNA levels and protein expression in asthmatic patients were negatively correlated with prebronchodilator and postbronchodilator FEV(1) value (r(2) >or= 0.193, P <or= .03), and they were positively related to airway smooth muscle areas (r(2) = 0.253, P = .01 and r(2) = 0.281, P = .005 for EDN1 mRNA and protein expression, respectively).

Conclusion: Increased EDN1 synthesis by the bronchial epithelium characterizes severe refractory asthma and correlates with airway remodeling and airflow obstruction.

Clinical implications: Targeting EDN1 might represent a novel therapeutic strategy for severe steroid-refractory asthma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / biosynthesis*
  • Adjuvants, Immunologic / genetics*
  • Anti-Inflammatory Agents / therapeutic use
  • Asthma / immunology
  • Asthma / metabolism*
  • Asthma / pathology
  • Asthma / physiopathology
  • Bronchi / immunology
  • Bronchi / metabolism
  • Bronchi / pathology
  • Dyspnea / immunology
  • Dyspnea / metabolism*
  • Dyspnea / pathology
  • Dyspnea / physiopathology
  • Endothelin-1 / biosynthesis*
  • Endothelin-1 / genetics*
  • Gene Expression Regulation / immunology*
  • Humans
  • Respiratory Mucosa / immunology
  • Respiratory Mucosa / metabolism*
  • Respiratory Mucosa / pathology
  • Respiratory Mucosa / physiopathology
  • Steroids / therapeutic use

Substances

  • Adjuvants, Immunologic
  • Anti-Inflammatory Agents
  • Endothelin-1
  • Steroids